US20170020795A1 - Metal salt compositions - Google Patents

Metal salt compositions Download PDF

Info

Publication number
US20170020795A1
US20170020795A1 US15/287,242 US201615287242A US2017020795A1 US 20170020795 A1 US20170020795 A1 US 20170020795A1 US 201615287242 A US201615287242 A US 201615287242A US 2017020795 A1 US2017020795 A1 US 2017020795A1
Authority
US
United States
Prior art keywords
zinc
metal salt
composition
weight
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/287,242
Inventor
Venda Porter Maloney
Vyoma Patel
Steven Wade Fisher
Andre Michelle Morgan
Michael Prencipe
Stanislav Jaracz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Priority to US15/287,242 priority Critical patent/US20170020795A1/en
Publication of US20170020795A1 publication Critical patent/US20170020795A1/en
Assigned to COLGATE-PALMOLIVE COMPANY reassignment COLGATE-PALMOLIVE COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MORGAN, ANDRE MICHELLE, PRENCIPE, MICHAEL, FISHER, STEVEN WADE, JARACZ, STANISLAV, PATEL, Vyoma, PORTER, VENDA
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the amount of a given metal salt which can be incorporated into an oral care product is often limited as a result of unfavorable effects on the sensory experience of the user, for example, astringency, taste and mouth feel.
  • Embodiments of the present invention provide compositions which address, inter alia, this problem.
  • the present invention provides an oral care composition
  • a first metal salt having a solubility of greater than 0.001 g/100 mL in water at 20° C.
  • a second metal salt having a solubility of 0.001 g/100 mL, or less, in water at 20° C.
  • a free water content of greater than about 10%, by weight.
  • the first metal salt and second metal salt are independently selected from a zinc salt, a stannous salt and a copper salt.
  • the second metal salt is present in an amount effective to provide a synergistic increase in delivery of the metal ion of the first or second metal salt.
  • Some embodiments provide a method of treating or preventing a disease or condition of the oral cavity comprising contacting an oral cavity surface of a patient in need thereof with any one of the compositions described herein.
  • ranges are used as a short hand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range.
  • soluble metal salt refers to a metal salt having a solubility of greater than 0.001 g/100 mL in water at 20° C.
  • insoluble metal salt refers to a metal salt having a solubility of 0.001 g/100 mL, or less, in water at 20° C.
  • the present invention provides an oral care composition
  • a first metal salt having a solubility of greater than 0.001 g/100 mL in water at 20° C.
  • a second metal salt having a solubility of 0.001 g/100 mL, or less, in water at 20° C.
  • a free water content of greater than about 10%, by weight.
  • the first metal salt and the second metal salt are independently selected from a zinc salt, a stannous salt and a copper salt.
  • the second metal salt is present in an amount effective to provide a synergistic increase in delivery of the metal ion of the first or second metal salt. In some embodiments, the second metal salt is present in an amount effective to provide a synergistic increase in the uptake of the metal ion of the first or second metal salt. In some embodiments, the delivery or uptake is synergistically increased in oral cavity soft tissue. In some embodiments, the delivery or uptake is synergistically increased in an oral cavity hard surface, e.g. a tooth. Some embodiments provide compositions wherein the second metal is present in an amount effective to provide a synergistic increase in delivery or uptake of the metal ion of the first metal salt.
  • the first metal salt and the second metal salt are salts of the same metal.
  • the first metal salt is selected from: zinc citrate, zinc chloride, zinc lactate, zinc nitrate, zinc acetate, zinc gluconate, zinc glycinate and zinc sulfate.
  • the zinc citrate is in the form of zinc citrate trihydrate.
  • the first metal salt is zinc citrate trihydrate.
  • the second metal salt is selected from: zinc oxide, zinc phosphate, zinc pyrophosphate, zinc silicate, zinc oleate, zinc hydroxide, zinc peroxide and zinc sulfide.
  • the composition comprises from about 0.1 to about 5%, by weight, of the first metal salt; and from about 0.05 to about 2%, by weight, of the second metal salt. In some embodiments, the composition comprises from about 0.5 to about 4%, by weight, of the first metal salt; and from about 0.1 to about 1.5%, by weight, of the second metal salt. In other embodiments, the composition comprises from about 1 to about 3%, by weight, of the first metal salt; and from about 0.2 to about 0.75%, by weight, of the second metal salt.
  • compositions comprising: about 2%, by weight, of the first metal salt; and about 0.25%, by weight, of the second metal salt. While other embodiments provide compositions comprising: about 2%, by weight, of the first metal salt; and about 0.5%, by weight, of the second metal salt.
  • compositions further comprise one or more components selected from a fluoride ion source; a tartar control agent; a buffering agent; an antibacterial agent; an abrasive; and a combination of two or more thereof.
  • compositions wherein at least one of the one or more components is a fluoride ion source selected from: stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and a combination of two or more thereof.
  • a fluoride ion source selected from: stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and a combination of two or more thereof.
  • optional additives may be included.
  • included are those provided in order to change appearance or aesthetic appeal, and/or to preserve the final product, and/or for taste/cosmetic appeal and/or as therapeutic and prophylactic ingredients for oral health, prevention or treatment of a condition or disorder of hard or soft tissue of the oral cavity, or the prevention or treatment of a physiological disorder or condition.
  • a preservative is present.
  • the preservative is selected from parabens, potassium sorbate, benzyl alcohol, phenoxyethanol, polyaminopropryl biguanide, caprylic acid, sodium benzoate and cetylpyridinium chloride.
  • the preservative is present at a concentration of about 0.0001 to about 1%, by weight.
  • Colorants such as dyes may be food color additives presently certified under the Food Drug & Cosmetic Act for use in food and ingested drugs, including dyes such as FD&C Red No. 3 (sodium salt of tetraiodofluorescein), Food Red 17, disodium salt of 6-hydroxy-5- ⁇ (2-methoxy-5-methyl-4-sulphophenyl)azo ⁇ -2-n-aphthalenesulfonic acid, Food Yellow 13, sodium salt of a mixture of the mono and disulphonic acids of quinophtalone or 2-(2-quinolyl) indanedione, FD&C Yellow No.
  • dyes such as FD&C Red No. 3 (sodium salt of tetraiodofluorescein), Food Red 17, disodium salt of 6-hydroxy-5- ⁇ (2-methoxy-5-methyl-4-sulphophenyl)azo ⁇ -2-n-aphthalenesulfonic acid, Food Yellow 13, sodium salt of a mixture of the mono and disulphonic acids of
  • Flavoring agents include, but are not limited to, natural and artificial flavors. These flavorings may be chosen from synthetic flavor oils and flavoring aromatics, and/or oils, oleo resins and extracts derived from plants, leaves, flowers, fruits and so forth, and combinations thereof. Representative flavor oils include: spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, and oil of bitter almonds. These flavoring agents can be used individually or in admixture. Commonly used flavors include mints such as peppermint, artificial vanilla, cinnamon derivatives, and various fruit flavors, whether employed individually or in admixture.
  • any flavoring agent or food additive such as those described in Chemicals Used in Food Processing, publication 1274 by the National Academy of Sciences, pages 63-258, may be used.
  • flavoring agents if included, are present at a concentration of from about 0.01 to about 1%, by weight. In some embodiments, the flavoring agent may be present at a concentration of about 0.2%, by weight.
  • Sweeteners include both natural and artificial sweeteners. Suitable sweeteners include water soluble sweetening agents such as monosaccharides, disaccharides and poysaccharides such as xylose, ribose, glucose (dextrose), mannose, galactose, fructose (levulose), sucrose (sugar), maltose, water soluble artificial sweeteners such as the soluble saccharin salts, i.e., sodium or calcium saccharin salts, cyclamate salts dipeptide based sweeteners, such a L-aspartic acid derived sweeteners, such as L-aspartyl-L-phenylalaine methyl ester (aspartame).
  • water soluble sweetening agents such as monosaccharides, disaccharides and poysaccharides such as xylose, ribose, glucose (dextrose), mannose, galactose, fructose (levulose), sucrose (su
  • the effective amount of sweetener is utilized to provide the level of sweetness desired for a particular composition, will vary with the sweetener selected. This amount will normally be from about 0.001 to about 5%, by weight. In some embodiments, the sweetener is sodium saccharin and is present at a concentration of about 0.01%, by weight.
  • Whitening agents material which is effective to effect whitening of a tooth surface to which it is applied, such as hydrogen peroxide and urea peroxide, high cleaning silica, preservatives, silicones, and chlorophyll compounds may be incorporated into the compositions of the present invention.
  • the compositions of this invention comprise a peroxide whitening agent, comprising a peroxide compound.
  • a peroxide compound is an oxidizing compound comprising a bivalent oxygen-oxygen group.
  • Peroxide compounds include peroxides and hydroperoxides, such as hydrogen peroxide, peroxides of alkali and alkaline earth metals, organic peroxy compounds, peroxy acids, pharmaceutically-acceptable salts thereof, and mixtures thereof.
  • Peroxides of alkali and alkaline earth metals include lithium peroxide, potassium peroxide, sodium peroxide, magnesium peroxide, calcium peroxide, barium peroxide, and mixtures thereof.
  • Organic peroxy compounds include carbamide peroxide (also known as urea hydrogen peroxide), glyceryl hydrogen peroxide, alkyl hydrogen peroxides, dialkyl peroxides, alkyl peroxy acids, peroxy esters, diacyl peroxides, benzoyl peroxide, and monoperoxyphthalate, and mixtures thereof.
  • Peroxy acids and their salts include organic peroxy acids such as alkyl peroxy acids, and monoperoxyphthalate and mixtures thereof, as well as inorganic peroxy acid salts such as persulfate, dipersulfate, percarbonate, perphosphate, perborate and persilicate salts of alkali and alkaline earth metals such as lithium, potassium, sodium, magnesium, calcium and barium, and mixtures thereof.
  • the peroxide compound comprises hydrogen peroxide, urea peroxide, sodium percarbonate and mixtures thereof.
  • the peroxide compound comprises hydrogen peroxide.
  • the peroxide compound consists essentially of hydrogen peroxide.
  • a non-peroxide whitening agent may be provided.
  • Whitening agents among those useful herein include non-peroxy compounds, such as chlorine dioxide, chlorites and hypochlorites.
  • Chlorites and hypochlorites include those of alkali and alkaline earth metals such as lithium, potassium, sodium, magnesium, calcium and barium.
  • Non-peroxide whitening agents also include colorants, such as titanium dioxide and hydroxyapatite.
  • One or more whitening agents are optionally present in a tooth-whitening effective total amount.
  • the whitening agent is separated from the aqueous carrier.
  • the whitening agent is separated from the aqueous carrier by encapsulation of the whitening agent.
  • breath freshening agents may be provided. Any orally acceptable breath freshening agent can be used, including without limitation. One or more breath freshening agents are optionally present in a breath freshening effective total amount.
  • compositions wherein at least one of the one or more components is a tartar control agent include phosphates and polyphosphates (for example pyrophosphates), polyaminopropanesulfonic acid (AMPS), polyolefin sulfonates, polyolefin phosphates, diphosphonates such as azacycloalkane-2,2-diphosphonates (e.g., azacycloheptane-2,2-diphosphonic acid), N-methyl azacyclopentane-2,3-diphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid (EHDP) and ethane-1-amino-1,1-diphosphonate, phosphonoalkane carboxylic acids and salts of any of these agents, for example their alkali metal and ammonium salts.
  • phosphates and polyphosphates for example pyrophosphates
  • AMPS polyaminopropanesulfonic acid
  • Useful inorganic phosphate and polyphosphate salts include monobasic, dibasic and tribasic sodium phosphates, sodium tripolyphosphate, tetrapolyphosphate, mono-, di-, tri- and tetrasodium pyrophosphates, sodium trimetaphosphate, sodium hexametaphosphate and mixtures thereof, wherein sodium can optionally be replaced by potassium or ammonium.
  • Other useful anticalculus agents include polycarboxylate polymers and polyvinyl methyl ether/maleic anhydride (PVME/MA) copolymers, such as those available under the Cantrezmt brand from ISP, Wayne, N.J.
  • PVME/MA polyvinyl methyl ether/maleic anhydride copolymers, such as those available under the Cantrezmt brand from ISP, Wayne, N.J.
  • a phosphate is present at a concentration of from about 0.01 to about 10%, by weight. In some embodiments, a
  • compositions wherein a buffering agent is present.
  • sodium phosphate monobasic is present at a concentration of from about 0.01 to about 5%, by weight. In some embodiments, sodium phosphate monobasic phosphate is present at a concentration of about 1%, by weight. In some embodiments, sodium phosphate dibasic is present at a concentration of from about 0.01 to about 5%, by weight. In some embodiments, sodium phosphate dibasic phosphate is present at a concentration of about 0.15%, by weight.
  • antimicrobial agents include antimicrobial (e.g., antibacterial) agents.
  • Any orally acceptable antimicrobial agent can be used, including Triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol); 8-hydroxyquinoline and salts thereof, zinc and stannous ion sources such as zinc citrate, zinc sulphate, zinc glycinate, sodium zinc citrate and stannous pyrophosphate; copper (II) compounds such as copper (I) chloride, fluoride, sulfate and hydroxide; phthalic acid and salts thereof such as magnesium monopotassium phthalate; sanguinarine; quaternary ammonium compounds, such as alkylpyridinium chlorides (e.g., cetylpyridinium chloride (CPC), combinations of CPC with zinc and/or enzymes, tetradecylpyridinium chloride, and N-tetradecyl-4-ethylpyridinium chloride); bisguanides,
  • the antimicrobial agent is present at a concentration of from about 0.001 to about 1%, by weight.
  • the antimicrobial agent is cetylpyridinium chloride.
  • cetylpyridinium chloride is present at a concentration of from about 0.001 to about 1%, by weight.
  • cetylpyridinium chloride is present at a concentration of about 0.05%, by weight.
  • Antioxidants are another class of optional additives. Any orally acceptable antioxidant can be used, including butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), vitamin A, carotenoids, vitamin E, flavonoids, polyphenols, ascorbic acid, herbal antioxidants, chlorophyll, melatonin, and mixtures thereof.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • vitamin A carotenoids
  • vitamin E flavonoids
  • polyphenols ascorbic acid
  • herbal antioxidants chlorophyll
  • melatonin and mixtures thereof.
  • a saliva stimulating agent useful for example in amelioration of dry mouth, may be included.
  • Any orally acceptable saliva stimulating agent can be used, including without limitation food acids such as citric, lactic, malic, succinic, ascorbic, adipic, fumaric, and tartaric acids, and mixtures thereof.
  • One or more saliva stimulating agents are optionally present in a saliva stimulating effective total amount.
  • an antiplaque agent e.g., plaque disrupting agent may be included.
  • Any orally acceptable antiplaque agent can be used, including without limitation stannous, copper, magnesium and strontium salts, dimethicone copolyols such as cetyl dimethicone copolyol, papain, glucoamylase, glucose oxidase, urea, calcium lactate, calcium glycerophosphate, strontium polyacrylates and mixtures thereof.
  • Optional desensitizing agents include potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate, strontium salts, and mixtures thereof.
  • Optional additives also include vitamins, herbs and proteins.
  • Vitamins include Vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, pantheon, retinyl palmitate, tocopherol acetate, and mixtures thereof.
  • Herbs such as Chamomilla recutita, Mentha piperita, Salvia oficinalis , and Commiphora myrrha may optionally be included.
  • Suitable proteins include milk proteins and enzymes such as peroxide-producing enzymes, amylase, plaque-disrupting agents such as papain, glucoamylase, glucose oxidase, and “next generation” enzymes.”
  • the composition has a free water content of greater than about 10%, by weight. In some embodiments, the composition has a free water content of greater than about 11%, by weight. In other embodiments, the composition has a free water content of greater than about 12%, by weight. Yet other embodiments provide compositions wherein the free water content is greater than about 13%, by weight. Still other embodiments provide compositions having a free water content of greater than about 14%, by weight. In some embodiments, the composition has a free water content of greater than about 15%, by weight. While other embodiments provide compositions have a free water content of greater than about 16%, by weight. In some embodiments, the composition has a free water content of about 17%, by weight. In some embodiments, the composition has a free water content of greater than about 17%, by weight. In some embodiments, the composition has a free water content of from about 10% to about 20%, by weight.
  • the soluble metal salt and insoluble metal salt are not contained in a film. In some embodiments, the soluble metal salt and insoluble metal salt are in a single phase.
  • Some embodiments provide a method of treating or preventing a disease or condition of the oral cavity comprising contacting an oral cavity surface of a patient in need thereof with any one of the compositions described herein.
  • the disease or condition of the oral cavity is halitosis.
  • the present invention provides a method of reducing volatile sulfur compounds in the oral cavity of a subject in need thereof.
  • the present invention provides a method for increasing the delivery of a metal ion to an oral cavity surface.
  • compositions described herein can be used, for example, for cavity prevention, whitening, plaque prevention or reduction, gingivitis prevention or reduction, tartar control, breath malodor prevention or reduction, and stain prevention.
  • the carrier is aqueous, comprising from about 5 to about 95%, by weight, water or from about 10 to about 70%, by weight, water. In other embodiments, the carrier is substantially non-aqueous. In a dentifrice carrier, water content can be from about 5 to about 70%, from about 10 to about 50%, or from about 20 to about 40%, by weight.
  • the carrier may comprise any of a variety of materials, including emulsifiers, thickeners, fillers, and preservatives.
  • the carrier may include a functional or active material, such as those described above.
  • the carrier comprises a humectant, such as glycerin, sorbitol or an alkylene glycol such as polyethylene glycol or propylene glycol.
  • the carrier comprises a humectant at a level of from about 10 to about 80% by weight, or about 20 to about 60% by weight of the composition.
  • Carrier compositions among those useful herein are disclosed in U.S. Pat. No. 5,695,746 to Garlick, Jr., et al. and U.S. Pat. No. 4,839,157 to Mei-King Ng et al.
  • Thickeners or gelling agents useful herein include inorganic, natural or synthetic thickeners or gelling agents.
  • the carrier comprises the thickener and gelling agent at total levels of from about 0.1 to about 15% by weight, or from about 0.4 to about 10% by weight of the composition.
  • thickeners and gelling agents useful herein include inorganic thickening silicas such as: an amorphous silica, for example Zeodent® 165 (Huber Corporation); Irish moss; iota-carrageenan; gum tragacanth; or polyvinylpyrrolidone.
  • the carrier comprises an abrasive or polishing agent, such as a silica, a calcined alumina, sodium bicarbonate, calcium carbonate, dicalcium phosphate or calcium pyrophosphate.
  • the carrier is clear.
  • the carrier comprises an abrasive at a level of from about 5 to about 70% by weight of the composition.
  • the compositions comprise a surfactant or mixture of surfactants.
  • surfactants among those useful herein include water-soluble salts of at least one higher fatty acid monoglyceride monosulfate, such as the sodium salt of the monsulfated monoglyceride of hydrogenated coconut oil fatty acids; cocamidopropyl betaine; a higher alkyl sulfate such as sodium lauryl sulfate; an alkyl aryl sulfonate such as sodium dodecyl benzene sulfonate; a higher alkyl sulfoacetate; sodium lauryl sulfoacetate; a higher fatty acid ester of 1,2-dihydroxy propane sulfonate; and a substantially saturated higher aliphatic acyl amides of a lower aliphatic amino carboxylic acid, such as those having 12 to 16 carbons in the fatty acid, alkyl or acyl radicals; and mixtures thereof.
  • Amides can be, for example, N-lauroyl sarcosine, and the sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine.
  • the surfactant is present at a concentration of from about 0.3 to about 5% by weight of composition, or about 0.5 to about 3% by weight of composition.
  • compositions as described herein can be prepared according to methods readily known to those skilled in the art.
  • Table 1 (below) provides the formulation for exemplary compositions of the present invention.
  • compositions were diluted with water (1:2) to form a slurry.
  • a saliva coated hydroxyapatite disk was added to the slurry.
  • the disk remained in the slurry for about 10 minutes and was then rinsed three times with 5 mL of water.
  • the disk was then digested with nitric acid and total zinc was measured by atomic absorption spectroscopy.
  • Pig tongue is a suitable tissue representing a human tongue.
  • Vitro-skin is a commercial product used as a standard for in-vitro skin related experiments.
  • compositions of the present invention which contain a combination of a soluble metal salt (e.g. zinc citrate) and an insoluble metal salt (e.g. zinc oxide).
  • a soluble metal salt e.g. zinc citrate
  • an insoluble metal salt e.g. zinc oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same.

Description

    BACKGROUND
  • The amount of a given metal salt which can be incorporated into an oral care product is often limited as a result of unfavorable effects on the sensory experience of the user, for example, astringency, taste and mouth feel.
  • These limits on metal salt concentration have made it difficult to deliver an effective amount of a metal ion to the soft and/or hard tissue of the oral cavity using an oral care composition. Embodiments of the present invention provide compositions which address, inter alia, this problem.
  • SUMMARY
  • In some embodiments, the present invention provides an oral care composition comprising: a first metal salt, having a solubility of greater than 0.001 g/100 mL in water at 20° C.; a second metal salt having a solubility of 0.001 g/100 mL, or less, in water at 20° C.; and a free water content of greater than about 10%, by weight. In some embodiments, the first metal salt and second metal salt are independently selected from a zinc salt, a stannous salt and a copper salt. In some embodiments, the second metal salt is present in an amount effective to provide a synergistic increase in delivery of the metal ion of the first or second metal salt.
  • Some embodiments provide a method of treating or preventing a disease or condition of the oral cavity comprising contacting an oral cavity surface of a patient in need thereof with any one of the compositions described herein.
  • DETAILED DESCRIPTION
  • As used throughout, ranges are used as a short hand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range.
  • In addition, all references cited herein are hereby incorporated by reference in their entireties.
  • In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
  • As used herein, the term “soluble metal salt” refers to a metal salt having a solubility of greater than 0.001 g/100 mL in water at 20° C.
  • As used herein, the term “insoluble metal salt” refers to a metal salt having a solubility of 0.001 g/100 mL, or less, in water at 20° C.
  • In some embodiments, the present invention provides an oral care composition comprising: a first metal salt, having a solubility of greater than 0.001 g/100 mL in water at 20° C.; a second metal salt having a solubility of 0.001 g/100 mL, or less, in water at 20° C.; and a free water content of greater than about 10%, by weight. In some embodiments, the first metal salt and the second metal salt are independently selected from a zinc salt, a stannous salt and a copper salt.
  • In some embodiments, the second metal salt is present in an amount effective to provide a synergistic increase in delivery of the metal ion of the first or second metal salt. In some embodiments, the second metal salt is present in an amount effective to provide a synergistic increase in the uptake of the metal ion of the first or second metal salt. In some embodiments, the delivery or uptake is synergistically increased in oral cavity soft tissue. In some embodiments, the delivery or uptake is synergistically increased in an oral cavity hard surface, e.g. a tooth. Some embodiments provide compositions wherein the second metal is present in an amount effective to provide a synergistic increase in delivery or uptake of the metal ion of the first metal salt.
  • In some embodiments, the first metal salt and the second metal salt are salts of the same metal.
  • In some embodiments, the first metal salt is selected from: zinc citrate, zinc chloride, zinc lactate, zinc nitrate, zinc acetate, zinc gluconate, zinc glycinate and zinc sulfate. In some embodiments, the zinc citrate is in the form of zinc citrate trihydrate. In some embodiments, the first metal salt is zinc citrate trihydrate.
  • In some embodiments, the second metal salt is selected from: zinc oxide, zinc phosphate, zinc pyrophosphate, zinc silicate, zinc oleate, zinc hydroxide, zinc peroxide and zinc sulfide.
  • In some embodiments, the composition comprises from about 0.1 to about 5%, by weight, of the first metal salt; and from about 0.05 to about 2%, by weight, of the second metal salt. In some embodiments, the composition comprises from about 0.5 to about 4%, by weight, of the first metal salt; and from about 0.1 to about 1.5%, by weight, of the second metal salt. In other embodiments, the composition comprises from about 1 to about 3%, by weight, of the first metal salt; and from about 0.2 to about 0.75%, by weight, of the second metal salt.
  • Yet further embodiments provide compositions comprising: about 2%, by weight, of the first metal salt; and about 0.25%, by weight, of the second metal salt. While other embodiments provide compositions comprising: about 2%, by weight, of the first metal salt; and about 0.5%, by weight, of the second metal salt.
  • In some embodiments, the compositions further comprise one or more components selected from a fluoride ion source; a tartar control agent; a buffering agent; an antibacterial agent; an abrasive; and a combination of two or more thereof.
  • Some embodiments provide compositions wherein at least one of the one or more components is a fluoride ion source selected from: stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and a combination of two or more thereof.
  • Other optional additives may be included. Among such optional additives, included are those provided in order to change appearance or aesthetic appeal, and/or to preserve the final product, and/or for taste/cosmetic appeal and/or as therapeutic and prophylactic ingredients for oral health, prevention or treatment of a condition or disorder of hard or soft tissue of the oral cavity, or the prevention or treatment of a physiological disorder or condition.
  • Some embodiments provide a composition wherein a preservative is present. In some embodiments, the preservative is selected from parabens, potassium sorbate, benzyl alcohol, phenoxyethanol, polyaminopropryl biguanide, caprylic acid, sodium benzoate and cetylpyridinium chloride. In some embodiments, the preservative is present at a concentration of about 0.0001 to about 1%, by weight.
  • Colorants such as dyes may be food color additives presently certified under the Food Drug & Cosmetic Act for use in food and ingested drugs, including dyes such as FD&C Red No. 3 (sodium salt of tetraiodofluorescein), Food Red 17, disodium salt of 6-hydroxy-5-{(2-methoxy-5-methyl-4-sulphophenyl)azo}-2-n-aphthalenesulfonic acid, Food Yellow 13, sodium salt of a mixture of the mono and disulphonic acids of quinophtalone or 2-(2-quinolyl) indanedione, FD&C Yellow No. (sodium salt of 4-p-sulfophenylazo-1-p-sulfophenyl-5-hydroxypyrazole-3 carboxylic acid), FD&C Yellow No. 6 (sodium salt of p-sulfophenylazo-B-naphtol-6-monosulfonate), FD&C Green No. 3 (disodium salt of 4-{[4-(N-ethyl-p-sulfobenzylamino)-phenyl]-(4-hydroxy-2-sulfoniumphenyl)-methylene}-[1-(N-ethyl-N-p-sulfobenzyl)-DELTA-3,5-cycl-ohexadienimine], FD&C Blue No. 1 (disodium salt of dibenzyldiethyl-diamino-triphenylcarbinol trisulfonic acid anhydrite), FD&C Blue No. 2 (sodium salt of disulfonic acid of indigotin) and mixtures thereof in various proportions. Typically, colorants if included are present in very small quantities.
  • Flavoring agents include, but are not limited to, natural and artificial flavors. These flavorings may be chosen from synthetic flavor oils and flavoring aromatics, and/or oils, oleo resins and extracts derived from plants, leaves, flowers, fruits and so forth, and combinations thereof. Representative flavor oils include: spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, and oil of bitter almonds. These flavoring agents can be used individually or in admixture. Commonly used flavors include mints such as peppermint, artificial vanilla, cinnamon derivatives, and various fruit flavors, whether employed individually or in admixture. Generally, any flavoring agent or food additive, such as those described in Chemicals Used in Food Processing, publication 1274 by the National Academy of Sciences, pages 63-258, may be used. Typically, flavoring agents, if included, are present at a concentration of from about 0.01 to about 1%, by weight. In some embodiments, the flavoring agent may be present at a concentration of about 0.2%, by weight.
  • Sweeteners include both natural and artificial sweeteners. Suitable sweeteners include water soluble sweetening agents such as monosaccharides, disaccharides and poysaccharides such as xylose, ribose, glucose (dextrose), mannose, galactose, fructose (levulose), sucrose (sugar), maltose, water soluble artificial sweeteners such as the soluble saccharin salts, i.e., sodium or calcium saccharin salts, cyclamate salts dipeptide based sweeteners, such a L-aspartic acid derived sweeteners, such as L-aspartyl-L-phenylalaine methyl ester (aspartame). In general, the effective amount of sweetener is utilized to provide the level of sweetness desired for a particular composition, will vary with the sweetener selected. This amount will normally be from about 0.001 to about 5%, by weight. In some embodiments, the sweetener is sodium saccharin and is present at a concentration of about 0.01%, by weight.
  • Whitening agents, material which is effective to effect whitening of a tooth surface to which it is applied, such as hydrogen peroxide and urea peroxide, high cleaning silica, preservatives, silicones, and chlorophyll compounds may be incorporated into the compositions of the present invention. In various embodiments, the compositions of this invention comprise a peroxide whitening agent, comprising a peroxide compound. A peroxide compound is an oxidizing compound comprising a bivalent oxygen-oxygen group. Peroxide compounds include peroxides and hydroperoxides, such as hydrogen peroxide, peroxides of alkali and alkaline earth metals, organic peroxy compounds, peroxy acids, pharmaceutically-acceptable salts thereof, and mixtures thereof. Peroxides of alkali and alkaline earth metals include lithium peroxide, potassium peroxide, sodium peroxide, magnesium peroxide, calcium peroxide, barium peroxide, and mixtures thereof. Organic peroxy compounds include carbamide peroxide (also known as urea hydrogen peroxide), glyceryl hydrogen peroxide, alkyl hydrogen peroxides, dialkyl peroxides, alkyl peroxy acids, peroxy esters, diacyl peroxides, benzoyl peroxide, and monoperoxyphthalate, and mixtures thereof. Peroxy acids and their salts include organic peroxy acids such as alkyl peroxy acids, and monoperoxyphthalate and mixtures thereof, as well as inorganic peroxy acid salts such as persulfate, dipersulfate, percarbonate, perphosphate, perborate and persilicate salts of alkali and alkaline earth metals such as lithium, potassium, sodium, magnesium, calcium and barium, and mixtures thereof. In various embodiments, the peroxide compound comprises hydrogen peroxide, urea peroxide, sodium percarbonate and mixtures thereof. In some embodiments, the peroxide compound comprises hydrogen peroxide. In some embodiments, the peroxide compound consists essentially of hydrogen peroxide. In some embodiments a non-peroxide whitening agent may be provided. Whitening agents among those useful herein include non-peroxy compounds, such as chlorine dioxide, chlorites and hypochlorites. Chlorites and hypochlorites include those of alkali and alkaline earth metals such as lithium, potassium, sodium, magnesium, calcium and barium. Non-peroxide whitening agents also include colorants, such as titanium dioxide and hydroxyapatite. One or more whitening agents are optionally present in a tooth-whitening effective total amount. In some embodiments the whitening agent is separated from the aqueous carrier. In some embodiments the whitening agent is separated from the aqueous carrier by encapsulation of the whitening agent.
  • Optionally, breath freshening agents may be provided. Any orally acceptable breath freshening agent can be used, including without limitation. One or more breath freshening agents are optionally present in a breath freshening effective total amount.
  • Other embodiments provide compositions wherein at least one of the one or more components is a tartar control agent. Tartar control agents among those useful herein include phosphates and polyphosphates (for example pyrophosphates), polyaminopropanesulfonic acid (AMPS), polyolefin sulfonates, polyolefin phosphates, diphosphonates such as azacycloalkane-2,2-diphosphonates (e.g., azacycloheptane-2,2-diphosphonic acid), N-methyl azacyclopentane-2,3-diphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid (EHDP) and ethane-1-amino-1,1-diphosphonate, phosphonoalkane carboxylic acids and salts of any of these agents, for example their alkali metal and ammonium salts. Useful inorganic phosphate and polyphosphate salts include monobasic, dibasic and tribasic sodium phosphates, sodium tripolyphosphate, tetrapolyphosphate, mono-, di-, tri- and tetrasodium pyrophosphates, sodium trimetaphosphate, sodium hexametaphosphate and mixtures thereof, wherein sodium can optionally be replaced by potassium or ammonium. Other useful anticalculus agents include polycarboxylate polymers and polyvinyl methyl ether/maleic anhydride (PVME/MA) copolymers, such as those available under the Cantrezmt brand from ISP, Wayne, N.J. In some embodiments, a phosphate is present at a concentration of from about 0.01 to about 10%, by weight. In some embodiments, a phosphate is present at a concentration of from about 1%, by weight.
  • Some embodiments provide compositions wherein a buffering agent is present. In some embodiments, sodium phosphate monobasic is present at a concentration of from about 0.01 to about 5%, by weight. In some embodiments, sodium phosphate monobasic phosphate is present at a concentration of about 1%, by weight. In some embodiments, sodium phosphate dibasic is present at a concentration of from about 0.01 to about 5%, by weight. In some embodiments, sodium phosphate dibasic phosphate is present at a concentration of about 0.15%, by weight.
  • Other optional additives include antimicrobial (e.g., antibacterial) agents. Any orally acceptable antimicrobial agent can be used, including Triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol); 8-hydroxyquinoline and salts thereof, zinc and stannous ion sources such as zinc citrate, zinc sulphate, zinc glycinate, sodium zinc citrate and stannous pyrophosphate; copper (II) compounds such as copper (I) chloride, fluoride, sulfate and hydroxide; phthalic acid and salts thereof such as magnesium monopotassium phthalate; sanguinarine; quaternary ammonium compounds, such as alkylpyridinium chlorides (e.g., cetylpyridinium chloride (CPC), combinations of CPC with zinc and/or enzymes, tetradecylpyridinium chloride, and N-tetradecyl-4-ethylpyridinium chloride); bisguanides, such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; halogenated bisphenolic compounds, such as 2,2′ methylenebis-(4-chloro-6-bromophenol); benzalkonium chloride; salicylanilide, domiphen bromide; iodine; sulfonamides; bisbiguanides; phenolics; piperidino derivatives such as delmopinol and octapinol; magnolia extract; grapeseed extract; thymol; eugenol; menthol; geraniol; carvacrol; citral; eucalyptol; catechol; 4-allylcatechol; hexyl resorcinol; methyl salicylate; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, neomycin, kanamycin and clindamycin; and mixtures thereof. A further illustrative list of useful antibacterial agents is provided in U.S. Pat. No. 5,776,435, Gaffar, et al., issued Jul. 7, 1998. In some embodiments, the antimicrobial agent is present at a concentration of from about 0.001 to about 1%, by weight. In some embodiments, the antimicrobial agent is cetylpyridinium chloride. In some embodiments, cetylpyridinium chloride is present at a concentration of from about 0.001 to about 1%, by weight. In other embodiments, cetylpyridinium chloride is present at a concentration of about 0.05%, by weight.
  • Antioxidants are another class of optional additives. Any orally acceptable antioxidant can be used, including butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), vitamin A, carotenoids, vitamin E, flavonoids, polyphenols, ascorbic acid, herbal antioxidants, chlorophyll, melatonin, and mixtures thereof.
  • Also optional, a saliva stimulating agent, useful for example in amelioration of dry mouth, may be included. Any orally acceptable saliva stimulating agent can be used, including without limitation food acids such as citric, lactic, malic, succinic, ascorbic, adipic, fumaric, and tartaric acids, and mixtures thereof. One or more saliva stimulating agents are optionally present in a saliva stimulating effective total amount.
  • Optionally, an antiplaque (e.g., plaque disrupting) agent may be included. Any orally acceptable antiplaque agent can be used, including without limitation stannous, copper, magnesium and strontium salts, dimethicone copolyols such as cetyl dimethicone copolyol, papain, glucoamylase, glucose oxidase, urea, calcium lactate, calcium glycerophosphate, strontium polyacrylates and mixtures thereof.
  • Optional desensitizing agents include potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate, strontium salts, and mixtures thereof.
  • Optional additives also include vitamins, herbs and proteins. Vitamins include Vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, pantheon, retinyl palmitate, tocopherol acetate, and mixtures thereof. Herbs such as Chamomilla recutita, Mentha piperita, Salvia oficinalis, and Commiphora myrrha may optionally be included. Suitable proteins include milk proteins and enzymes such as peroxide-producing enzymes, amylase, plaque-disrupting agents such as papain, glucoamylase, glucose oxidase, and “next generation” enzymes.”
  • In some embodiments, the composition has a free water content of greater than about 10%, by weight. In some embodiments, the composition has a free water content of greater than about 11%, by weight. In other embodiments, the composition has a free water content of greater than about 12%, by weight. Yet other embodiments provide compositions wherein the free water content is greater than about 13%, by weight. Still other embodiments provide compositions having a free water content of greater than about 14%, by weight. In some embodiments, the composition has a free water content of greater than about 15%, by weight. While other embodiments provide compositions have a free water content of greater than about 16%, by weight. In some embodiments, the composition has a free water content of about 17%, by weight. In some embodiments, the composition has a free water content of greater than about 17%, by weight. In some embodiments, the composition has a free water content of from about 10% to about 20%, by weight.
  • In some embodiments, the soluble metal salt and insoluble metal salt are not contained in a film. In some embodiments, the soluble metal salt and insoluble metal salt are in a single phase.
  • Some embodiments provide a method of treating or preventing a disease or condition of the oral cavity comprising contacting an oral cavity surface of a patient in need thereof with any one of the compositions described herein. In other embodiments, the disease or condition of the oral cavity is halitosis. In some embodiments, the present invention provides a method of reducing volatile sulfur compounds in the oral cavity of a subject in need thereof. In further embodiments, the present invention provides a method for increasing the delivery of a metal ion to an oral cavity surface.
  • In certain embodiments, the compositions described herein can be used, for example, for cavity prevention, whitening, plaque prevention or reduction, gingivitis prevention or reduction, tartar control, breath malodor prevention or reduction, and stain prevention.
  • The specific composition of the carrier preferably depends on the intended use of the composition. In various embodiments, the carrier is aqueous, comprising from about 5 to about 95%, by weight, water or from about 10 to about 70%, by weight, water. In other embodiments, the carrier is substantially non-aqueous. In a dentifrice carrier, water content can be from about 5 to about 70%, from about 10 to about 50%, or from about 20 to about 40%, by weight.
  • The carrier may comprise any of a variety of materials, including emulsifiers, thickeners, fillers, and preservatives. In some embodiments, the carrier may include a functional or active material, such as those described above.
  • In some embodiments, the carrier comprises a humectant, such as glycerin, sorbitol or an alkylene glycol such as polyethylene glycol or propylene glycol. In some embodiments, the carrier comprises a humectant at a level of from about 10 to about 80% by weight, or about 20 to about 60% by weight of the composition. Carrier compositions among those useful herein are disclosed in U.S. Pat. No. 5,695,746 to Garlick, Jr., et al. and U.S. Pat. No. 4,839,157 to Mei-King Ng et al.
  • Thickeners or gelling agents useful herein include inorganic, natural or synthetic thickeners or gelling agents. In some configurations, the carrier comprises the thickener and gelling agent at total levels of from about 0.1 to about 15% by weight, or from about 0.4 to about 10% by weight of the composition. Examples of thickeners and gelling agents useful herein include inorganic thickening silicas such as: an amorphous silica, for example Zeodent® 165 (Huber Corporation); Irish moss; iota-carrageenan; gum tragacanth; or polyvinylpyrrolidone.
  • In certain embodiments, the carrier comprises an abrasive or polishing agent, such as a silica, a calcined alumina, sodium bicarbonate, calcium carbonate, dicalcium phosphate or calcium pyrophosphate. In various embodiments, the carrier is clear. In various embodiments, the carrier comprises an abrasive at a level of from about 5 to about 70% by weight of the composition.
  • In some embodiments, the compositions comprise a surfactant or mixture of surfactants. Surfactants among those useful herein include water-soluble salts of at least one higher fatty acid monoglyceride monosulfate, such as the sodium salt of the monsulfated monoglyceride of hydrogenated coconut oil fatty acids; cocamidopropyl betaine; a higher alkyl sulfate such as sodium lauryl sulfate; an alkyl aryl sulfonate such as sodium dodecyl benzene sulfonate; a higher alkyl sulfoacetate; sodium lauryl sulfoacetate; a higher fatty acid ester of 1,2-dihydroxy propane sulfonate; and a substantially saturated higher aliphatic acyl amides of a lower aliphatic amino carboxylic acid, such as those having 12 to 16 carbons in the fatty acid, alkyl or acyl radicals; and mixtures thereof. Amides can be, for example, N-lauroyl sarcosine, and the sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine. In various embodiments, the surfactant is present at a concentration of from about 0.3 to about 5% by weight of composition, or about 0.5 to about 3% by weight of composition.
  • Compositions as described herein can be prepared according to methods readily known to those skilled in the art.
  • Embodiments of the present invention are further described in the following examples. The examples are merely illustrative and do not in any way limit the scope of the invention as described and claimed.
  • EXAMPLES Example 1
  • Table 1 (below) provides the formulation for exemplary compositions of the present invention.
  • TABLE 1
    Ingredient % w/w
    Gantrez (13% solution) 11.5
    Glycerin 11.5
    Zeodent 105 10
    Zeodent 114 10
    Polyethylene glycol 3
    Tetrapotassium pyrophosphate 2.4
    Zinc citrate trihydrate  0.1-5
    Zeodent 165 1.8
    Sodium lauryl sulfate 1.5
    Sodium hydroxide 1.3
    Flavor 1.2
    Titanium dioxide 1
    Sodium monofluorophosphate 0.8
    Sodium CMC 0.6
    Carrageenan 0.4
    Sodium saccharin 0.3
    Zinc oxide 0.05-2
    Water 17.6
    Sorbitol q.s.
  • Example 2
  • The delivery of zinc from exemplary compositions of the present invention to hydroxyapatite was compared to zinc delivery from compositions containing either a soluble or insoluble metal salt alone. The evaluation was performed using the following experimental procedure.
  • Compositions were diluted with water (1:2) to form a slurry. A saliva coated hydroxyapatite disk was added to the slurry. The disk remained in the slurry for about 10 minutes and was then rinsed three times with 5 mL of water. The disk was then digested with nitric acid and total zinc was measured by atomic absorption spectroscopy.
  • The data described in Table 2 (below) demonstrates that the addition of an insoluble metal salt (e.g. zinc oxide) to a composition comprising a soluble metal salt (e.g. zinc citrate) synergistically increases the delivery of the metal (zinc) to hydroxyapatite.
  • TABLE 2
    Zinc uptake
    Formula (ug/disk) Total Zinc (%) Soluble Zinc (%)
    2% Zn Citrate 33.7 ± 5.0 0.71 0.29
    2% Zn Citrate + 69.0 ± 8.5 0.88 0.23
    0.25% ZnO
    2% Zn Citrate + 135.9 ± 11.8 1.13 0.36
    0.5% ZnO
    1.0% ZnO in silica base  5.9 ± 0.4 0.60 0.07
  • Example 3
  • The uptake of zinc in the pig tongue and vitro skin was evaluated using the test procedures below.
  • Pig Tongue
  • Remove muscle portion of the tongue. Cut into 12 mm circles with cork borer. Glue circles to glass plates. Transfer into 24-well plate. Incubate with 1 mL of PBS buffer for 30 minutes at room temperature. Aspirate buffer, incubate for 2 minutes with 1 mL of 1:2 slurry of studied paste at 37° C. Aspirate slurry and rinse tissue 3× with 2 mL of deionized water. Transfer into a tube and digest with 1 mL of conc. nitric acid (HNOA) overnight. Fill up to 15 mL with deionized water. Centrifuge for 30 minutes at 2500 RPM to obtain clear supernatant for submission for zinc analysis.
  • Vitro-Skin
  • Cut Vitro-skin (IMS Inc., Portland, Me.) into uniform circles of diameter between 10 to 14 mm. Cork borer could be used. The exact diameter will be necessary to calculate uptake per square centimeter. To remove the silicone coating, rinse the Vitro-skin circles (in bulk) 3 times with hexanes for 5 minutes. Air dry to evaporate hexanes. Soak Vitro-skin in sterilized and cleared saliva overnight in disposable polystyrene Falcon tube (mfc. code 352057). Use 1 mL of saliva per tissue. Perform in triplicate. Aspirate saliva, add 1 mL of 1:2 paste slurry and incubate for 2 minutes in 37° C. water bath. Operate quickly as uptake depends on exposure time at all temperatures. Aspirate the slurry and rinse 3-times with 5 mL of DI water for 10 seconds each. Use vortex for rinsing (max speed). Transfer the tissue into new polystyrene Falcon tube (mfc. code 352095). Process all samples at same speed. Add 1 mL of concentrated nitric acid to the tissue and incubate overnight. The tissue should dissolve completely. Add enough deionized water to fill it to 10 mL line. Shake well. Do not filter. Submit for zinc analysis. The obtained level of zinc (typically in ppm) must be multiplied by the total volume (10× in this case) to get μg of zinc per tissue (UT). Table 3 (below) describes the data generated in the pig tongue and vitro-skin experiments described herein.
  • To calculate uptake of zinc per square centimeter, the following formula can be used:

  • U R=2*U T/(π*d 2) [μg/cm2]

  • wherein:

  • U R=(relative) zinc uptake per square centimeter of Vitro-skin (both sides)
  • UT=zinc uptake per tissue
  • d=diameter of the tissue in centimeters
  • TABLE 3
    Zn uptake to pig Zn uptake to Vitro- Soluble
    Formula tongue (μg/cm2) skin (μg/cm2) zinc (%)
    2% Zn Citrate 13.5 ± 1.1 1.8 ± 0.5 0.24
    2% Zn Citrate + 25.4 ± 7.4 12.0 ± 0.3  0.33
    0.5% ZnO
    1% ZnO not available 2.2 ± 0.2 0.07
    3% Zn Lactate 21.2 ± 5.8 6.9 ± 1.0 0.52
  • Pig tongue is a suitable tissue representing a human tongue. Vitro-skin is a commercial product used as a standard for in-vitro skin related experiments.
  • The data described in Table 3 (above) demonstrates that metal salt uptake is synergistically increased by exemplary compositions of the present invention, which contain a combination of a soluble metal salt (e.g. zinc citrate) and an insoluble metal salt (e.g. zinc oxide).
  • As those skilled in the art will appreciate, numerous changes and modifications may be made to the embodiments described herein without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the appended claims.

Claims (18)

What is claimed is:
1. An oral care composition comprising:
a first metal salt, having a solubility of greater than 0.001 g/100 mL in water at 20° C.;
a second metal salt, having a solubility of 0.001 g/100 mL, or less, in water at 20° C.; and
a free water content of greater than about 10%, by weight;
wherein the first metal salt and the second metal salt are independently selected from a zinc salt, a stannous salt and a copper salt; and
wherein the second metal salt is present in an amount effective to provide a synergistic increase in delivery of the metal ion of the first or second metal salt.
2. The composition of claim 1, wherein the first metal salt and the second metal salt are salts of the same metal.
3. The composition of claim 1, wherein the second metal salt is present in an amount effective to provide a synergistic increase in delivery of the metal ion of the first metal salt.
4. The composition of claim 1, wherein the first metal salt is selected from: zinc citrate trihydrate, zinc chloride, zinc lactate, zinc nitrate, zinc acetate, zinc gluconate, zinc glycinate and zinc sulfate.
5. The composition of claim 1, wherein the second metal salt is selected from: zinc oxide, zinc phosphate, zinc pyrophosphate, zinc silicate, zinc oleate, zinc hydroxide, zinc peroxide, and zinc sulfide.
6. The composition of claim 1, comprising:
from about 0.1 to about 5%, by weight, of said first metal salt; and
from about 0.05 to about 2%, by weight, of said second metal salt.
7. The composition of claim 1, comprising:
from about 0.5 to about 4%, by weight, of said first metal salt; and
from about 0.1 to about 1.5%, by weight, of said second metal salt.
8. The composition of claim 1, comprising:
from about 1 to about 3%, by weight, of said first metal salt; and
from about 0.2 to about 0.75%, by weight, of said second metal salt.
9. The composition of claim 1, comprising:
about 2%, by weight, of said first metal salt; and
about 0.25%, by weight, of said second metal salt.
10. The composition of claim 1, comprising:
about 2%, by weight, of said first metal salt; and
about 0.5%, by weight, of said second metal salt.
11. The composition of claim 1, further comprising one or more components selected from a fluoride ion source; a tartar control agent; a buffering agent; an antibacterial agent; an abrasive; and a combination of two or more thereof.
12. The composition of claim 11, wherein at least one of the one or more components is a fluoride ion source selected from: stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and a combination of two or more thereof.
13. The composition of claim 11, wherein at least one of the one or more components is a tartar control agent selected from: sodium tripolyphosphate, sodium tetrapolyphosphate, mono-, di-, tri- and tetrasodium pyrophosphates, sodium trimetaphosphate, sodium hexametaphosphate; potassium tripolyphosphate, potassium tetrapolyphosphate, mono-, di-, tri- and tetrapotassium pyrophosphates, potassium trimetaphosphate, potassium hexametaphosphate; and a combination of two or more thereof.
14. The composition of claim 1, wherein the composition comprises greater than about 15%, by weight, free water.
15. A method of treating or preventing a disease or condition of the oral cavity comprising contacting an oral cavity surface of a patient in need thereof with the composition of claim 1.
16. The method of claim 15, wherein the disease or condition of the oral cavity is halitosis.
17. The composition of claim 1, wherein
the first metal salt is selected from: zinc citrate trihydrate, zinc chloride, zinc lactate, zinc nitrate, zinc acetate, zinc gluconate, zinc glycinate and zinc sulfate,
the second metal salt is selected from: zinc oxide, zinc phosphate, zinc pyrophosphate, zinc silicate, zinc oleate, zinc hydroxide, zinc peroxide, and zinc sulfide; and,
the composition comprises
from about 0.1 to about 5%, by weight, of said first metal salt; and
from about 0.05 to about 2%, by weight, of said second metal salt.
18. The composition of claim 17, wherein the composition comprises greater than about 15%, by weight, free water.
US15/287,242 2010-12-21 2016-10-06 Metal salt compositions Abandoned US20170020795A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/287,242 US20170020795A1 (en) 2010-12-21 2016-10-06 Metal salt compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2010/061414 WO2012087288A2 (en) 2010-12-21 2010-12-21 Metal salt compositions
US201313996036A 2013-06-20 2013-06-20
US15/287,242 US20170020795A1 (en) 2010-12-21 2016-10-06 Metal salt compositions

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/996,036 Continuation US9486396B2 (en) 2010-12-21 2010-12-21 Metal salt compositions
PCT/US2010/061414 Continuation WO2012087288A2 (en) 2010-12-21 2010-12-21 Metal salt compositions

Publications (1)

Publication Number Publication Date
US20170020795A1 true US20170020795A1 (en) 2017-01-26

Family

ID=44625359

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/996,036 Active US9486396B2 (en) 2010-12-21 2010-12-21 Metal salt compositions
US15/287,242 Abandoned US20170020795A1 (en) 2010-12-21 2016-10-06 Metal salt compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/996,036 Active US9486396B2 (en) 2010-12-21 2010-12-21 Metal salt compositions

Country Status (14)

Country Link
US (2) US9486396B2 (en)
EP (1) EP2654684B1 (en)
JP (1) JP5947810B2 (en)
CN (1) CN103260591B (en)
AR (1) AR084445A1 (en)
AU (1) AU2010365811B2 (en)
BR (1) BR112013015972B1 (en)
CA (1) CA2822025C (en)
MX (1) MX343586B (en)
MY (1) MY162655A (en)
RU (1) RU2560687C2 (en)
SG (1) SG190904A1 (en)
TW (1) TWI461202B (en)
WO (1) WO2012087288A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10555883B2 (en) 2015-07-01 2020-02-11 Colgate-Palmolive Company Oral care compositions and methods of use
US11058617B2 (en) 2018-12-20 2021-07-13 Colgate-Palmolive Company Methods
US11135144B2 (en) 2014-12-26 2021-10-05 Colgate-Palmolive Company Low water dentifrice compositions
US11529295B2 (en) 2019-09-25 2022-12-20 Church & Dwight Co., Inc. Oral care composition
US11752075B2 (en) 2021-05-25 2023-09-12 Colgate-Palmolive Company Oral care compositions
US12109442B2 (en) 2014-12-26 2024-10-08 Colgate-Palmolive Company Oral care compositions and methods of use

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN03992A (en) * 2012-12-05 2015-10-02 Colgate Palmolive Co
US10494589B2 (en) 2012-12-19 2019-12-03 Colgate-Palmolive Company Method for indicating time for washing or indicating delivery of antibacterial agent
WO2014098821A1 (en) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Method for indicating time for washing or indicating delivery of antibacterial agent
RU2636221C2 (en) * 2012-12-24 2017-11-21 Колгейт-Палмолив Компани Oral care composition
CN104721063B (en) * 2013-12-19 2018-05-08 高露洁-棕榄公司 Dentrifice composition comprising zinc oxide and zinc citrate
CN109908017A (en) * 2013-12-19 2019-06-21 高露洁-棕榄公司 Oral care composition
CN108210355B (en) 2013-12-19 2022-02-18 高露洁-棕榄公司 Oral care compositions
WO2015171837A1 (en) 2014-05-09 2015-11-12 The Procter & Gamble Company Oral compositions containing zinc
CN106999383B (en) * 2014-12-16 2020-11-24 高露洁-棕榄公司 Metal salt composition
CN107427423A (en) * 2015-03-30 2017-12-01 荷兰联合利华有限公司 Solid oral care composition
EP3380070A1 (en) 2015-12-30 2018-10-03 Colgate-Palmolive Company Oral care compositions
CN108472208B (en) 2015-12-30 2021-12-10 高露洁-棕榄公司 Personal care compositions
MX370238B (en) 2015-12-30 2019-12-06 Colgate Palmolive Co Oral care compositions.
CA3009827A1 (en) 2015-12-30 2017-07-06 Colgate-Palmolive Company Personal care compositions comprising tripolyphosphate and tin fluoride or tin chloride
CN106994103B (en) * 2016-01-26 2021-08-10 白育纶 Mouthwash composition
US20170367939A1 (en) * 2016-06-24 2017-12-28 Colgate-Palmolive Company Oral Care Compositions and Methods of Use
US20170367948A1 (en) * 2016-06-24 2017-12-28 Colgate-Palmolive Company Oral Care Compositions and Methods of Use
BR112017019268A2 (en) 2016-06-24 2018-07-17 Colgate-Palmolive Company oral hygiene compositions and methods of use.
US10058493B2 (en) 2016-12-21 2018-08-28 Colgate-Palmolive Company Oral care compositions and methods of use
RU2727696C1 (en) * 2016-12-21 2020-07-23 Колгейт-Палмолив Компани Oral care compositions and methods for use thereof
CA3095052C (en) * 2018-03-29 2023-08-29 The Procter & Gamble Company Oral care compositions comprising a stannous ion source and an acidic amino acid for promoting gum health
US11253449B2 (en) * 2018-12-26 2022-02-22 Colgate-Palmolive Company Oral care compositions
CN114449991B (en) 2019-09-30 2024-07-16 宝洁公司 Oral care compositions with anticaries activity
WO2021062607A1 (en) 2019-09-30 2021-04-08 The Procter & Gamble Company Oral care compositions comprising hops beta acid and amino acid
CN111299067A (en) * 2020-03-26 2020-06-19 江苏百赛飞生物科技有限公司 Dip-coating curing production line
WO2021195590A1 (en) 2020-03-27 2021-09-30 Colgate-Palmolive Company Oral care compositions and methods of use
US11701314B2 (en) 2020-07-31 2023-07-18 Colgate-Palmolive Company Processes and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1806733A (en) * 1931-05-26 Signors to acme pishing tool co
US3622662A (en) * 1969-04-21 1971-11-23 Colgate Palmolive Co Stable dental cream
US4100269A (en) * 1973-06-28 1978-07-11 Lever Brothers Company Anticalculus dentifrice
US5256396A (en) * 1990-01-24 1993-10-26 Colgate-Palmolive Company Topical composition
US6169118B1 (en) * 1998-11-12 2001-01-02 Block Drug Company, Inc. Flavor blend for masking unpleasant taste of zinc compounds
US20110229534A1 (en) * 2006-10-05 2011-09-22 The Trustees Of Columbia University In The City Of New York Non-Irritating Oral Care Formulations
US20120201902A1 (en) * 2009-06-30 2012-08-09 The Trustees Of Columbia University In The City Of New York Antimicrobial/preservative compositions comprising botanicals

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622622A (en) 1967-11-03 1971-11-23 Parke Davis & Co {60 -{8 p-(dimethylaminoalkoxy) phenyl{9 -{60 {40 -nitro-4-methoxystilbene compounds and methods for their production
NO130143B (en) * 1969-04-21 1974-07-15 Colgate Palmolive Co
US3624199A (en) * 1969-04-21 1971-11-30 James Norfleet Dental cream
US4154815A (en) 1970-04-01 1979-05-15 Lever Brothers Company Zinc and enzyme toothpowder dentifrice
JPS5019515B2 (en) 1971-09-21 1975-07-08
JPS5146375B2 (en) 1971-10-06 1976-12-08
US4022880A (en) 1973-09-26 1977-05-10 Lever Brothers Company Anticalculus composition
US4082841A (en) 1975-10-10 1978-04-04 Lever Brothers Company Dentifrice
US4144323A (en) 1978-06-15 1979-03-13 Lever Brothers Company Novel anticalculus compositions
JPS5846483B2 (en) 1979-09-20 1983-10-17 ライオン株式会社 Oral composition
DE3069906D1 (en) 1979-10-02 1985-02-14 Gaba International Ag Oral compositions with stabilised zinc salts
EP0152836B1 (en) * 1984-02-20 1990-06-20 Blendax GmbH Oral hygiene composition
NZ214031A (en) 1984-12-11 1989-05-29 Colgate Palmolive Co Astringent dentifrice containing synthetic, precipitated, amorphous silica gel as polishing agent
US5288480A (en) 1987-01-30 1994-02-22 Colgate-Palmolive Co. Antiplaque antibacterial oral composition
US4839157A (en) 1987-04-17 1989-06-13 Colgate-Palmolive Company Stable hydrogen peroxide dental gel containing fumed silicas
GB8922434D0 (en) * 1989-10-05 1989-11-22 Unilever Plc Oral compositions
US5188820A (en) * 1989-10-05 1993-02-23 Chesebrough-Pond's Usa Co., Dividion Of Conopco, Inc. Method of inhibiting plaque on teeth by applying an oral composition
GB8922594D0 (en) 1989-10-06 1989-11-22 Unilever Plc Oral compositions
JPH05930A (en) 1991-06-25 1993-01-08 Lion Corp Composition for oral cavity
US5240697A (en) * 1991-10-17 1993-08-31 Colgate-Palmolive Company Desensitizing anti-tartar dentifrice
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
US5603922A (en) 1995-08-08 1997-02-18 Enamelon Inc. Processes and compositions for the remineralization of teeth
US6036944A (en) 1995-08-08 2000-03-14 Enamelon, Inc. Processes for the remineralization and mineralization of teeth
NZ335780A (en) 1996-10-23 2001-01-26 Univ New York State Res Found Compositions to control oral microbial oxidation-reduction (Eh) levels and treat gingivitis-periodontitis
JPH11228368A (en) * 1998-02-18 1999-08-24 Sunstar Inc Composition for oral cavity
JPH11246375A (en) 1998-02-27 1999-09-14 Sunstar Inc Composition for oral cavity
US5858333A (en) 1998-08-07 1999-01-12 Enamelon, Inc. Two-part oral products and methods of using same to remineralize teeth
JP2009520829A (en) * 2005-12-20 2009-05-28 ザ プロクター アンド ギャンブル カンパニー Oral care composition comprising zinc and phytate
US20080138298A1 (en) 2006-12-12 2008-06-12 The Procter & Gamble Company Oral care compositions comprising zinc and phytate
AU2010254205B2 (en) * 2009-05-26 2014-10-23 Colgate-Palmolive Company Dentifrice composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1806733A (en) * 1931-05-26 Signors to acme pishing tool co
US3622662A (en) * 1969-04-21 1971-11-23 Colgate Palmolive Co Stable dental cream
US4100269A (en) * 1973-06-28 1978-07-11 Lever Brothers Company Anticalculus dentifrice
US5256396A (en) * 1990-01-24 1993-10-26 Colgate-Palmolive Company Topical composition
US6169118B1 (en) * 1998-11-12 2001-01-02 Block Drug Company, Inc. Flavor blend for masking unpleasant taste of zinc compounds
US20110229534A1 (en) * 2006-10-05 2011-09-22 The Trustees Of Columbia University In The City Of New York Non-Irritating Oral Care Formulations
US20120201902A1 (en) * 2009-06-30 2012-08-09 The Trustees Of Columbia University In The City Of New York Antimicrobial/preservative compositions comprising botanicals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EFSA, "Scientific Opinion of the Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request from the Commision on magnesium aspartate, potassium aspartate, magnesium potassium aspartate, calcium aspartate, zinc aspartate . . . purposes to food supplements". The EFSA Journal (2008) 883, pages 1-23. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135144B2 (en) 2014-12-26 2021-10-05 Colgate-Palmolive Company Low water dentifrice compositions
US12109442B2 (en) 2014-12-26 2024-10-08 Colgate-Palmolive Company Oral care compositions and methods of use
US10555883B2 (en) 2015-07-01 2020-02-11 Colgate-Palmolive Company Oral care compositions and methods of use
US11058617B2 (en) 2018-12-20 2021-07-13 Colgate-Palmolive Company Methods
US11529295B2 (en) 2019-09-25 2022-12-20 Church & Dwight Co., Inc. Oral care composition
US11752075B2 (en) 2021-05-25 2023-09-12 Colgate-Palmolive Company Oral care compositions

Also Published As

Publication number Publication date
MY162655A (en) 2017-06-30
MX2013007226A (en) 2013-08-15
MX343586B (en) 2016-11-10
EP2654684A2 (en) 2013-10-30
CN103260591B (en) 2016-10-26
BR112013015972A2 (en) 2018-07-10
US20130287709A1 (en) 2013-10-31
WO2012087288A2 (en) 2012-06-28
SG190904A1 (en) 2013-07-31
JP5947810B2 (en) 2016-07-06
JP2014507399A (en) 2014-03-27
CA2822025A1 (en) 2012-06-28
TWI461202B (en) 2014-11-21
EP2654684B1 (en) 2017-06-07
AR084445A1 (en) 2013-05-15
US9486396B2 (en) 2016-11-08
AU2010365811A1 (en) 2013-05-09
TW201231056A (en) 2012-08-01
CA2822025C (en) 2016-12-06
AU2010365811B2 (en) 2016-02-11
CN103260591A (en) 2013-08-21
WO2012087288A3 (en) 2012-12-27
RU2560687C2 (en) 2015-08-20
BR112013015972B1 (en) 2018-12-04
RU2013133680A (en) 2015-01-27

Similar Documents

Publication Publication Date Title
US9486396B2 (en) Metal salt compositions
US11278477B2 (en) Dentifrice composition comprising zinc oxide and zinc citrate
US20220016001A1 (en) Oral Care Compositions
US10357438B2 (en) Metal salt compositions
CN111032001A (en) Oral care compositions
RU2726203C2 (en) Compositions for oral care with corrected taste

Legal Events

Date Code Title Description
STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: APPEAL READY FOR REVIEW

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

AS Assignment

Owner name: COLGATE-PALMOLIVE COMPANY, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PORTER, VENDA;FISHER, STEVEN WADE;MORGAN, ANDRE MICHELLE;AND OTHERS;SIGNING DATES FROM 20110126 TO 20110304;REEL/FRAME:068809/0528